甘氨酸转运蛋白1抑制剂Iclepertin(BI 425809)及其主要代谢产物的稳定同位素合成。

IF 0.9 4区 医学 Q4 BIOCHEMICAL RESEARCH METHODS Journal of labelled compounds & radiopharmaceuticals Pub Date : 2023-09-20 DOI:10.1002/jlcr.4063
Bachir Latli, Matt J. Hrapchak, Maxim Chevliakov, Lalith P. Samankumara, Rogelio P. Frutos, Heewon Lee
{"title":"甘氨酸转运蛋白1抑制剂Iclepertin(BI 425809)及其主要代谢产物的稳定同位素合成。","authors":"Bachir Latli,&nbsp;Matt J. Hrapchak,&nbsp;Maxim Chevliakov,&nbsp;Lalith P. Samankumara,&nbsp;Rogelio P. Frutos,&nbsp;Heewon Lee","doi":"10.1002/jlcr.4063","DOIUrl":null,"url":null,"abstract":"<p>Stable isotope labeled <b>Iclepertin (BI 425809, 1)</b> and its major metabolites are needed as internal standards in bioanalytical studies. <b>BI 425809</b> consists of two main building blocks, 5-methylsulfonyl-2-[(1<i>R</i>)-2,2,2-trifluoro-1-methyl-ethoxy]benzoic acid (<b>2</b>) and 3-[(1<i>R</i>,5<i>R</i>)-3-azabicyclo[3.1.0]hexan-5-yl]-5-(trifluoromethyl)isoxazole (<b>3</b>) linked to each other via an amide bond. We used fluoro[<sup>13</sup>C<sub>6</sub>]benzene as the starting material in the preparation of <b>[</b><sup><b>13</b></sup><b>C</b><sub><b>6</b></sub><b>]-2</b>. This intermediate was then employed to access carbon 13 labeled <b>Iclepertin</b> (<b>[</b><sup><b>13</b></sup><b>C</b><sub><b>6</b></sub><b>]-1</b>) and other metabolites. The major metabolite <b>BI 761036</b> (<b>6</b>), which resulted from cytochrome P450 oxidation and amide hydrolysis of <b>BI 425809</b>, was prepared labeled with carbon 13 and nitrogen 15 via two synthetic routes. In the first route, diethyl [<sup>13</sup>C<sub>3</sub>]malonate, [<sup>13</sup>C]methyl iodide, and hydroxyl[<sup>15</sup>N]amine were used to provide <b>[</b><sup><b>13</b></sup><b>C</b><sub><b>4</b></sub>,<sup><b>15</b></sup><b>N]-BI 761036 ([</b><sup><b>13</b></sup><b>C</b><sub><b>4</b></sub>,<sup><b>15</b></sup><b>N]-6a)</b> in 13 steps in 6% overall yield, whereas in the second route, [<sup>13</sup>C<sub>3</sub>]propargyl alcohol, potassium [<sup>13</sup>C]cyanide, and [<sup>15</sup>N]ammonia were used to furnish <b>[</b><sup><b>13</b></sup><b>C</b><sub><b>4</b></sub>,<sup><b>15</b></sup><b>N]-BI 761036 ([</b><sup><b>13</b></sup><b>C</b><sub><b>4</b></sub>,<sup><b>15</b></sup><b>N]-6b)</b> in 11 steps in 1% overall yield. The detailed stable isotope synthesis of <b>1</b> and its major metabolites is described.</p>","PeriodicalId":16288,"journal":{"name":"Journal of labelled compounds & radiopharmaceuticals","volume":null,"pages":null},"PeriodicalIF":0.9000,"publicationDate":"2023-09-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":"{\"title\":\"Stable isotope synthesis of glycine transporter 1 inhibitor Iclepertin (BI 425809) and its major metabolites\",\"authors\":\"Bachir Latli,&nbsp;Matt J. Hrapchak,&nbsp;Maxim Chevliakov,&nbsp;Lalith P. Samankumara,&nbsp;Rogelio P. Frutos,&nbsp;Heewon Lee\",\"doi\":\"10.1002/jlcr.4063\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p>Stable isotope labeled <b>Iclepertin (BI 425809, 1)</b> and its major metabolites are needed as internal standards in bioanalytical studies. <b>BI 425809</b> consists of two main building blocks, 5-methylsulfonyl-2-[(1<i>R</i>)-2,2,2-trifluoro-1-methyl-ethoxy]benzoic acid (<b>2</b>) and 3-[(1<i>R</i>,5<i>R</i>)-3-azabicyclo[3.1.0]hexan-5-yl]-5-(trifluoromethyl)isoxazole (<b>3</b>) linked to each other via an amide bond. We used fluoro[<sup>13</sup>C<sub>6</sub>]benzene as the starting material in the preparation of <b>[</b><sup><b>13</b></sup><b>C</b><sub><b>6</b></sub><b>]-2</b>. This intermediate was then employed to access carbon 13 labeled <b>Iclepertin</b> (<b>[</b><sup><b>13</b></sup><b>C</b><sub><b>6</b></sub><b>]-1</b>) and other metabolites. The major metabolite <b>BI 761036</b> (<b>6</b>), which resulted from cytochrome P450 oxidation and amide hydrolysis of <b>BI 425809</b>, was prepared labeled with carbon 13 and nitrogen 15 via two synthetic routes. In the first route, diethyl [<sup>13</sup>C<sub>3</sub>]malonate, [<sup>13</sup>C]methyl iodide, and hydroxyl[<sup>15</sup>N]amine were used to provide <b>[</b><sup><b>13</b></sup><b>C</b><sub><b>4</b></sub>,<sup><b>15</b></sup><b>N]-BI 761036 ([</b><sup><b>13</b></sup><b>C</b><sub><b>4</b></sub>,<sup><b>15</b></sup><b>N]-6a)</b> in 13 steps in 6% overall yield, whereas in the second route, [<sup>13</sup>C<sub>3</sub>]propargyl alcohol, potassium [<sup>13</sup>C]cyanide, and [<sup>15</sup>N]ammonia were used to furnish <b>[</b><sup><b>13</b></sup><b>C</b><sub><b>4</b></sub>,<sup><b>15</b></sup><b>N]-BI 761036 ([</b><sup><b>13</b></sup><b>C</b><sub><b>4</b></sub>,<sup><b>15</b></sup><b>N]-6b)</b> in 11 steps in 1% overall yield. The detailed stable isotope synthesis of <b>1</b> and its major metabolites is described.</p>\",\"PeriodicalId\":16288,\"journal\":{\"name\":\"Journal of labelled compounds & radiopharmaceuticals\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.9000,\"publicationDate\":\"2023-09-20\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of labelled compounds & radiopharmaceuticals\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1002/jlcr.4063\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"BIOCHEMICAL RESEARCH METHODS\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of labelled compounds & radiopharmaceuticals","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/jlcr.4063","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"BIOCHEMICAL RESEARCH METHODS","Score":null,"Total":0}
引用次数: 1

摘要

生物分析研究中需要稳定同位素标记的Iclepertin(BI 425809,1)及其主要代谢产物作为内标。BI 425809由两个主要组成部分组成,5-甲基磺酰基-2-[(1R)-2,2,2-三氟-1-甲基-乙氧基]苯甲酸(2)和3-[(1R,5R)-3-氮杂双环[3.1.0]己-5-基]-5-(三氟甲基)异恶唑(3),它们通过酰胺键相互连接。我们使用氟[13 C6]苯作为起始原料制备[13 C6]-2。然后将该中间体用于获得碳13标记的Iclepertin([13 C6]-1)和其他代谢物。主要代谢产物BI 761036(6)是由细胞色素P450氧化和BI 425809的酰胺水解产生的,通过两种合成途径用碳13和氮15标记。在第一路线中,[13 C3]丙二酸二乙酯、[13 C]甲基碘和羟基[15 N]胺用于在13个步骤中以6%的总产率提供[13 C4,15 N]-BI 761036([13 C4、15 N]-6a),而在第二路线中,使用[13 C3]丙炔醇、[13 C]氰化钾和[15 N]氨用于在11个步骤中提供[13 C4,15 N]-BI 762036([1 3 C4,15N]-6b),以1%的总产率。详细介绍了1及其主要代谢产物的稳定同位素合成。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

摘要图片

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Stable isotope synthesis of glycine transporter 1 inhibitor Iclepertin (BI 425809) and its major metabolites

Stable isotope labeled Iclepertin (BI 425809, 1) and its major metabolites are needed as internal standards in bioanalytical studies. BI 425809 consists of two main building blocks, 5-methylsulfonyl-2-[(1R)-2,2,2-trifluoro-1-methyl-ethoxy]benzoic acid (2) and 3-[(1R,5R)-3-azabicyclo[3.1.0]hexan-5-yl]-5-(trifluoromethyl)isoxazole (3) linked to each other via an amide bond. We used fluoro[13C6]benzene as the starting material in the preparation of [13C6]-2. This intermediate was then employed to access carbon 13 labeled Iclepertin ([13C6]-1) and other metabolites. The major metabolite BI 761036 (6), which resulted from cytochrome P450 oxidation and amide hydrolysis of BI 425809, was prepared labeled with carbon 13 and nitrogen 15 via two synthetic routes. In the first route, diethyl [13C3]malonate, [13C]methyl iodide, and hydroxyl[15N]amine were used to provide [13C4,15N]-BI 761036 ([13C4,15N]-6a) in 13 steps in 6% overall yield, whereas in the second route, [13C3]propargyl alcohol, potassium [13C]cyanide, and [15N]ammonia were used to furnish [13C4,15N]-BI 761036 ([13C4,15N]-6b) in 11 steps in 1% overall yield. The detailed stable isotope synthesis of 1 and its major metabolites is described.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
3.30
自引率
0.00%
发文量
57
审稿时长
1 months
期刊介绍: The Journal of Labelled Compounds and Radiopharmaceuticals publishes all aspects of research dealing with labeled compound preparation and applications of these compounds. This includes tracer methods used in medical, pharmacological, biological, biochemical and chemical research in vitro and in vivo. The Journal of Labelled Compounds and Radiopharmaceuticals devotes particular attention to biomedical research, diagnostic and therapeutic applications of radiopharmaceuticals, covering all stages of development from basic metabolic research and technological development to preclinical and clinical studies based on physically and chemically well characterized molecular structures, coordination compounds and nano-particles.
期刊最新文献
Issue Information Preliminary Research of Radiolabeled Atezolizumab for the Noninvasive Evaluation of TNBC PD-L1 Expression In Vivo Issue Information Abstracts From the 29th International Isotope Society UK Meeting 17th November 2023 Lead-212/Bismuth-212 In Vivo Generator Based on Ultrasmall Silver Telluride Nanoparticles
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1